Abstract
Background Recently, several novel RSV immunisation products that protect infants and older adults against RSV disease have been licensed in Europe. We estimated the effectiveness and efficiency of introducing these RSV immunisation strategies in Germany.
Methods We used a Bayesian framework to fit an age-structured dynamic transmission model of RSV to sentinel surveillance and RSV-specific hospitalisation data in Germany from 2015-2019. The calibrated model was used to evaluate different RSV intervention strategies over five years: long-acting, single-dose monoclonal antibodies (mAbs) in high-risk infants aged 1-5 months; long-acting mAbs in all infants aged 1-5 months; seasonal vaccination of pregnant women and one-time seasonal vaccination of older adults (75+/65+/55+ years). We performed sensitivity analysis on vaccine uptake, seasonal vs. year-round maternal vaccination, and the effect of under-ascertainment for older adults.
Results The model was able to match the various RSV datasets. Replacing the current short-acting mAB for high-risk infants with long-acting mAbs prevented 1.1% of RSV-specific hospitalisations in infants per year at the same uptake. Expanding the long-acting mAB programme to all infants prevented 39.3% of infant hospitalisations per year. Maternal vaccination required a larger number to be immunised to prevent one additional hospitalisation than a long-acting mAB for the same uptake. Vaccination of adults older than 75 years at an uptake of 40% in addition to Nirsevimab in all infants prevented an additional 4.5% of all RSV-hospitalisations over five years, with substantial uncertainty in the correction for under-ascertainment of the RSV burden.
Conclusions Immunisation has the potential to reduce the RSV disease burden in Germany.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
FK, MTS, US, OW, MK, TH, MJ, VS and SF received funding for a modelling project of RSV immunisation strategies in Germany from the Federal Joint Committee in 2019-2023 (grant number: 01VSF18015). SF was supported by a Sir Henry Dale Fellowship jointly funded by the Wellcome Trust and the Royal Society (Grant number 208812/Z/17/Z). MJ received funding from NIHR Health Protection Research Unit in Modelling and Health Economics (grant code NIHR200908) and Immunisation (NIHR200929). DH received funding from NIHR Health Protection Research Unit in Modelling and Health Economics (grant code NIHR200908). FGS holds an honorary, non-remunerated role at LSHTM.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Federal Office for Social Security gave approval for using the data of the health insurance Techniker Krankenkasse for this analysis.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
↵* shared first authorship
Data Availability
This study uses claims data from a German health insurance company that are subject to strict data protection rules according to the German Code of Social Law (“SGB V”). Therefore, these data cannot be made publicly accessible. Public data of the sentinel surveillance can be found online at https://influenza.rki.de. Public data on intensive care stays and in-hospital mortality are available online at https://datenbrowser.inek.org. The programming code for the model and other, public data are available at https://github.com/fkrauer/RSV-VACC-DE.
